The straight answer
Here is the honest answer: no peptide is a proven treatment for chronic fatigue (ME/CFS). A few compounds in our library target the mitochondria and metabolism, which is a reasonable-sounding idea because low energy is the hallmark of this illness. But none of them has been tested in people with chronic fatigue in a real trial, and the one mitochondrial peptide that was tested for fatigue in a related disease failed to beat placebo. If someone promises you a peptide that fixes ME/CFS, they are selling hope, not evidence.
What actually treats it
There is no cure or FDA-approved drug for ME/CFS, so care focuses on managing it: pacing (carefully staying within your energy limits to avoid post-exertional crashes) is the cornerstone, alongside treating the things that make it worse, such as poor sleep, pain, dizziness on standing (POTS/orthostatic intolerance), and depression or anxiety. A clinician who knows ME/CFS can also check for treatable causes of fatigue that mimic it, like thyroid problems, anemia, sleep apnea, or low iron.
From our library
Compounds here with any tie to chronic fatigue — rated honestly for this specific use.
- Early
MOTS-c
SpeculativeMOTS-c is a mitochondrial peptide, and since ME/CFS involves problems with how cells make energy, researchers have floated it as a theoretical candidate (there is even a 2025 preprint arguing the case). But the evidence is all mice, rats, and lab dishes. No human has ever been given MOTS-c for chronic fatigue, or for anything else, in a published trial. Interesting idea, zero human proof.
- Early
SS-31 (elamipretide)
SpeculativeSS-31 protects the energy-making parts of cells, so on paper it fits the mitochondrial theory of fatigue. It is the closest thing here to a real test: in people with primary mitochondrial myopathy (a different disease), a short trial improved walking, but the larger 24-week trial did not beat placebo on fatigue. It has never been tested in ME/CFS. Its one FDA approval is for a rare condition, Barth syndrome, not fatigue.
- Early
NAD+
SpeculativeNAD+ is heavily marketed for energy and fatigue, and cells do need it to make energy. But the best human trials show that boosting NAD+ reliably raises NAD+ levels without reliably changing how people actually feel or function. There is no good trial showing it helps chronic fatigue specifically. IV NAD+ drips, the most hyped version, have essentially no controlled evidence at all.
Also being studied (not in our library)
- Rintatolimod (Ampligen) — Not a peptide, but worth knowing as the drug most specifically studied for ME/CFS. It is an immune-modulating molecule that showed modest improvements in some trials; it is approved in Argentina and remains investigational and unapproved in the US. Mentioned so you know the real research pipeline, not because we endorse it.
Bottom line
No peptide on this site is a proven treatment for chronic fatigue, and the ones with any plausible tie are unproven mitochondrial compounds tested only in animals or in other diseases. Please do not spend money or delay real care chasing them.